The invention relates to the use of 2-amino-nicotinamide derivatives of formula I wherein n is from 1 up to and including 6； W is O or S； R 1 and R 3 represent independently of each other hydrogen, lower alkyl or lower acyl； R 2 represents a cycloalkyl group, an aryl group, or a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms and 0, 1 or 2 heteroatoms independently from each other selected from the group consisting of oxygen and sulfur, which groups in each case are unsubstituted or mono- or polysubstituted； R and R' are independently of each other hydrogen or lower alkyl； X represents an aryl group, or a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms and 0, 1 or 2 heteroatoms independently from each other selected from the group consisting of oxygen and sulfur, which groups in each case are unsubstituted or mono- or polysubstituted； or a N-oxide, a possible tautomer thereof or a pharmaceutically acceptable salt of such a compound, alone or in combination with one or more other pharmaceutically active compounds for the preparation of a pharmaceutical composition for use for therapy of a disease which responds to an inhibition of the VEGF-receptor tyrosine kinase activity； and to new 2-amino-nicotinamide derivatives of formula I and processes for the preparation thereof.
